Interferon tau
Also known as: IFN-τ, IFNT, Interferon tau, oIFN-τ, Ovine interferon tau, Pregnancy recognition signal, Trophoblast interferon
Source Interferon tau at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Interferon tau (IFN‑τ) is a type I interferon produced exclusively by the trophoblast of early ruminant embryos. In cattle, sheep and goats it serves as the primary pregnancy‑recognition signal, preventing luteolysis and supporting implantation. Research also highlights its broader roles in stimulating uterine nutrient transport, modulating immune responses and influencing neuro‑endocrine axes, and it is being explored for anti‑inflammatory and metabolic applications in animal models.
Mechanism of Action
IFN‑τ binds the ubiquitously expressed type I interferon receptor (IFNAR), activating JAK‑STAT pathways that induce classical interferon‑stimulated genes. In the ruminant uterus it also engages STAT‑independent routes that up‑regulate genes for glucose and amino‑acid transport, especially arginine, which triggers the mTOR cascade to promote conceptus cell proliferation. A key reproductive effect is the inhibition of uterine oxytocin‑receptor expression, thereby blocking prostaglandin F2α‑mediated luteolysis. Systemically, IFN‑τ can stimulate the hypothalamic‑pituitary‑adrenal axis and suppress thyroid, gonadal and growth‑hormone axes.
What the Research Shows
A body of animal research demonstrates that IFN‑τ is essential for maternal recognition of pregnancy in ruminants, acting as an antiluteolytic factor by silencing uterine oxytocin receptors and preventing prostaglandin F2α release (Forde & Lonergan, 2017). It cooperates with progesterone to enhance uterine expression of nutrient‑transporters, proteases and growth‑factors, thereby fostering conceptus growth (Bazer et al., 2015). Evolutionary studies show multiple IFN‑τ gene variants with differing antiviral and antiproliferative activities, suggesting functional diversification (Ealy & Wooldridge, 2017). Beyond reproduction, IFN‑τ exhibits low cytotoxicity, antiviral, antiproliferative and anti‑inflammatory properties, and early investigations propose utility in metabolic and autoimmune disease models (Bazer & Thatcher, 2017). Neuro‑endocrine effects include activation of the HPA axis and suppression of thyroid, gonadal and GH axes, though reports are conflicting (Jones & Kennedy, 1993).
Reported Benefits
In ruminants, IFN‑τ reliably signals pregnancy, prevents luteolysis and improves early embryonic survival, as evidenced by multiple reproductive studies. It enhances uterine nutrient transport and activates mTOR‑driven conceptus proliferation, supporting implantation and placental development. Its low cytotoxicity and anti‑inflammatory actions have prompted exploratory work on metabolic and autoimmune disease mitigation in animal models. These benefits are currently limited to pre‑clinical and veterinary contexts.
Limitations of the Evidence
The precise IFN‑τ concentration needed for pregnancy maintenance remains undefined, and the relative importance of its various signaling pathways is still debated. Most data derive from cattle, sheep and goat studies; no human or non‑ruminant efficacy data exist. Reports on neuro‑endocrine effects are contradictory, and the relevance of IFN‑τ polymorphisms to function is unresolved. Consequently, therapeutic translation beyond veterinary research is speculative.
Safety Considerations
Animal investigations describe IFN‑τ as having low cytotoxicity and a favorable tolerability profile when administered experimentally. Nonetheless, systemic exposure can stimulate the hypothalamic‑pituitary‑adrenal axis and suppress thyroid, gonadal and growth‑hormone axes, indicating potential endocrine side‑effects. No human safety data are available, and long‑term effects in livestock have not been fully characterized.
How It Is Administered
Research‑grade IFN‑τ has been delivered to animals by intravenous, subcutaneous injection or oral gavage, typically as a recombinant protein formulation. Dosing regimens vary across studies and are not standardized for clinical use. Formulations are experimental and intended for laboratory or veterinary investigation only.
Routes of Administration
Goals & Uses
- Antiviral therapyInfectious DiseaseLow
- Multiple sclerosis treatmentAutoimmune / NeuroinflammatoryLow
- Enhance embryo implantationReproductiveModerate
- Lupus / SLEAutoimmuneUnknown
- Antiviral activityInfectious DiseaseLow
- Immunomodulation in autoimmune diseasesAutoimmuneLow
- Inflammatory bowel diseaseGastroenterologyLow
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe psychiatric disordersPsychiatricModerate
- Autoimmune hepatitisHepatic / AutoimmuneHigh
- Hypersensitivity to interferon tau or excipientsAllergy / ImmunologicHigh
Adverse Effects
- HepatotoxicityHepaticUncommonLiver injury or dysfunction
- Flu‑like symptomsSystemicUnknown
- Injection site reactionsLocalCommon
- Flu-like symptoms (fever, chills, myalgia)SystemicCommon
- Neuropsychiatric effectsNeurological / PsychiatricUncommon
- Hematologic changes (leukopenia, thrombocytopenia)HematologicUncommon
- FatigueGeneralCommonLow energy or tiredness
Drug Interactions
- Myelosuppressive agentsModerate
- Immunosuppressants (e.g., corticosteroids)Moderate
- Hepatotoxic drugsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric populationsAgeRelative
- Pre-existing autoimmune conditionsAutoimmuneRelative
- Non‑ruminant speciesSpeciesRelative
Regulatory Status
- European UnionUnapprovedNo EMA marketing authorization.
- United StatesUnapprovedInvestigational only; no FDA clearance.
- United KingdomInvestigationalNo MHRA approval; research use only
No regulatory approval for human or animal use; employed solely in pre‑clinical and veterinary research.
Evidence & Sources
- Journal ArticleModerateMathew DJ, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateBazer FW, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateForde N, Lonergan P2017-01-01T00:00:00.000000Z
- Journal ArticleModerateJones TH, Kennedy RL1993-01-01T00:00:00.000000Z
- Journal ArticleModerateEaly AD, Wooldridge LK2017-01-01T00:00:00.000000Z
- Journal ArticleModerateBazer FW, Thatcher WW2017-01-01T00:00:00.000000Z
Frequently Asked Questions
What role does interferon tau play in early pregnancy of cattle?
IFN‑τ is secreted by the early embryo and binds uterine receptors to block oxytocin‑receptor expression, preventing prostaglandin F2α release and luteolysis. This antiluteolytic action maintains the corpus luteum and progesterone production, which are essential for pregnancy continuation.
Can interferon tau be used to treat human diseases?
Current evidence is limited to animal studies. While IFN‑τ shows anti‑inflammatory and metabolic effects in rodents and livestock, no human clinical trials have been reported, and it is not approved for any human indication.
Are there any known side effects of interferon tau in animals?
Experimental work notes low cytotoxicity, but systemic IFN‑τ can activate the HPA axis and suppress thyroid, gonadal and growth‑hormone axes, suggesting possible endocrine disturbances. Detailed safety profiles and long‑term outcomes remain under investigation.
How is interferon tau administered in research settings?
Researchers have administered recombinant IFN‑τ by intravenous or subcutaneous injection, and occasionally by oral gavage, using purified protein solutions. Dosage and frequency depend on the specific experimental design.
Why is interferon tau specific to ruminants?
Genomic analyses show IFN‑τ genes are present only in pecoran ruminants, having evolved from an ancestral IFN‑omega gene with a trophoblast‑specific promoter. This restriction underlies its unique role as a pregnancy‑recognition signal in these species.
What is Interferon tau?
Interferon tau (IFN‑τ) is a type I interferon produced exclusively by the trophoblast of early ruminant embryos. In cattle, sheep and goats it serves as the primary pregnancy‑recognition signal, preventing luteolysis and supporting implantation. Research also highlights its broader roles in stimulating uterine nutrient transport, modulating immune responses and influencing neuro‑endocrine axes, and it is being explored for anti‑inflammatory and metabolic applications in animal models.
What is Interferon tau used for?
Interferon tau is educationally associated with: Antiviral therapy, Multiple sclerosis treatment, Enhance embryo implantation, Lupus / SLE, Antiviral activity, Immunomodulation in autoimmune diseases, Inflammatory bowel disease. Educational only — not medical advice.
How is Interferon tau administered?
Recorded routes of administration: Intramuscular, Intravenous, Oral, Subcutaneous.
What are the potential side effects of Interferon tau?
Reported adverse effects include: Hepatotoxicity, Flu‑like symptoms, Injection site reactions, Flu-like symptoms (fever, chills, myalgia), Neuropsychiatric effects, Hematologic changes (leukopenia, thrombocytopenia), Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid Interferon tau?
Recorded contraindications: Severe hepatic impairment, Severe psychiatric disorders, Autoimmune hepatitis, Hypersensitivity to interferon tau or excipients. Consult a qualified clinician before use.